Cagrilintide (AM833) vs GHK-Cu
Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Cagrilintide (AM833) and GHK-Cu (also searched as GHK-Cu vs Cagrilintide (AM833)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Cagrilintide (AM833) centers on metabolic, while GHK-Cu leans toward skin. On indexed research, GHK-Cu is ahead (Cagrilintide (AM833): 3 studies, Human clinical; GHK-Cu: 5, Preclinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Cagrilintide (AM833) is strongest for metabolic; GHK-Cu for skin.
- •Evidence: Cagrilintide (AM833) Human clinical (3 studies) vs GHK-Cu Preclinical (5).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Long-Acting Amylin Receptor Agonist | Weight Loss & Diabetes
Copper Peptide | Skin Regeneration & Anti-Aging Compound
Cagrilintide (AM833) vs GHK-Cu: side-by-side
| Metric | Cagrilintide (AM833) | GHK-Cu |
|---|---|---|
| Class | Weight Loss | Skin |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human clinical | Preclinical |
| Studies indexed | 3 | 5 |
| Research level | Extensively Studied | Well Studied |
| Strongest effect | Metabolic & appetite | Skin & aesthetics |
| Healing & recovery | 0.0 | 4.0▲ |
| Muscle & body comp | 0.0 | 1.0▲ |
| Metabolic & appetite | 4.0▲ | 3.0 |
| Neuro & mood | 0.0 | 2.0▲ |
| Sleep & circadian | 0.0 | 1.0▲ |
| Inflammation & immune | 0.0 | 4.0▲ |
| Skin & aesthetics | 0.0 | 5.0▲ |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Cagrilintide (AM833) | GHK-Cu |
|---|---|---|
| Mechanism | Long-acting amylin analog | Copper-binding tripeptide (GHK-Cu); tissue-remodeling / regenerative signaling |
| Route | Subcutaneous injection | Topical / subcutaneous |
| Half-life | ~7–8 days | — |
| Duration of action | Weekly dosing (investigational) | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Cagrilintide (AM833)?
Cagrilintide (AM833) is a long-acting amylin analog investigated for once-weekly subcutaneous use in obesity and type 2 diabetes, most notably combined with semaglutide as CagriSema.
Full Cagrilintide (AM833) profile, mechanism & studies →What is GHK-Cu?
Copper-binding tripeptide widely used in skin, hair, and wound-healing contexts, with systemic effects explored in research.
Full GHK-Cu profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | GHK-Cu | 4.0/5 effect signal |
| Muscle | GHK-Cu | 1.0/5 effect signal |
| Metabolic | Cagrilintide (AM833) | 4.0/5 effect signal |
| Neuro | GHK-Cu | 2.0/5 effect signal |
| Sleep | GHK-Cu | 1.0/5 effect signal |
| Inflammation | GHK-Cu | 4.0/5 effect signal |
| Skin | GHK-Cu | 5.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Cagrilintide (AM833) and GHK-Cu?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Cagrilintide (AM833) vs GHK-Cu: side effects
No community-reported effects logged yet.
- improved skin texture18
- localized irritation5
- transient tingling4
- gi upset1
- headache1
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Cagrilintide (AM833) has 3 approved studies indexed (Human clinical), and GHK-Cu has 5 (Preclinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Cagrilintide (AM833) or GHK-Cu better?
It depends on your goal. Cagrilintide (AM833) is strongest for metabolic; GHK-Cu for skin. GHK-Cu has more indexed studies (5). See the goal-by-goal breakdown above.
Is Cagrilintide (AM833) or GHK-Cu better for weight loss?
Cagrilintide (AM833) shows the stronger metabolic & appetite profile (4.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.
Is Cagrilintide (AM833) or GHK-Cu better for muscle?
GHK-Cu leads on the muscle & body-composition axis (1.0/5).
Which has more research, Cagrilintide (AM833) or GHK-Cu?
Cagrilintide (AM833) has 3 approved studies indexed (Human clinical); GHK-Cu has 5 (Preclinical). Higher counts mean more to read, not proven superiority.
Can you stack Cagrilintide (AM833) and GHK-Cu?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Cagrilintide (AM833) vs GHK-Cu?
Cagrilintide (AM833): no community-reported effects logged yet. GHK-Cu: improved skin texture, localized irritation, transient tingling. These are anonymous reports, not incidence rates — see each profile.
Is Cagrilintide (AM833) or GHK-Cu FDA-approved?
Cagrilintide (AM833) is a research-use compound and is not FDA-approved. GHK-Cu is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is GHK-Cu better than Cagrilintide (AM833)?
For skin, GHK-Cu has the edge; for metabolic, Cagrilintide (AM833) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Cagrilintide (AM833) and GHK-Cu are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.